The company expects net product revenues from sales of zynlonta to be approximately $15.8M for the third quarter ended September 30, with cash and cash equivalents totaling $234.7M as of September 30, 2025. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6M, the company would have had approximately $292.3M of cash and cash equivalents as of that date.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT: